Communiqués Alto Neuroscience, Inc.

Actions

ANRO

US02157Q1094

Recherche biotechnologique et médicale

Marché Fermé - NYSE 22:00:02 05/10/2026			Varia. 5j.	Varia. 1 janv.
24,01 ^USD	-3,19%		-9,94%	+34,89%

02/10	Un initié d’Alto Neuroscience a vendu des actions pour 3 567 247 dollars, selon un récent dépôt auprès de la Commission américaine des valeurs mobilières (SEC)	MT
27/08	Alto Neuroscience promeut Nick Smith aux postes de président et de directeur financier	MT

Communiqués

09/09	Alto Neuroscience Announces Participation in Upcoming Investor Conferences	BU
27/08	Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer	BU
12/08	Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights	BU
13/07	Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock	BU
15/06	Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia	BU
28/05	Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors	BU
15/05	Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award	BU
13/05	Alto Neuroscience : Corporate Presentation	PU
13/05	Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights	BU
11/05	Alto Neuroscience Announces Participation in Upcoming Investor Conferences	BU
04/05	Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting	BU
21/04	Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression	BU
01/04	Alto Neuroscience : Corporate - April 2026	PU
01/04	Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements	BU
16/03	Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum	AQ
16/03	Alto Neuroscience Announces $120 Million Private Placement Financing	BU
16/03	Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights	BU
13/03	Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum	BU
26/02	Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders	PR
23/02	Alto Neuroscience Announces Participation in Upcoming Investor Conferences	BU
16/02	Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia	AQ
13/02	Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia	BU
03/02	Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment	BU
14/01	Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression	BU
13/01	Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology	BU